• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance

      Thumbnail
      View / Download
      1.2 Mb
      Author(s)
      Mutlu, M.
      Raza, U.
      Saatci, Ö.
      Eyüpoğlu, E.
      Yurdusev, E.
      Şahin, Ö.
      Date
      2016-06
      Source Title
      Journal of Molecular Medicine
      Print ISSN
      0946-2716
      Publisher
      Springer Verlag
      Volume
      94
      Issue
      6
      Pages
      629 - 644
      Language
      English
      Type
      Review
      Item Usage Stats
      267
      views
      601
      downloads
      Abstract
      MicroRNAs (miRNAs) are 20–22-nucleotide small endogenous non-coding RNAs which regulate gene expression at post-transcriptional level. In the last two decades, identification of almost 2600 miRNAs in human and their potential to be modulated opened a new avenue to target almost all hallmarks of cancer. miRNAs have been classified as tumor suppressors or oncogenes depending on the phenotype they induce, the targets they modulate, and the tissue where they function. miR-200c, an illustrious tumor suppressor, is one of the highly studied miRNAs in terms of development, stemness, proliferation, epithelial-mesenchymal transition (EMT), therapy resistance, and metastasis. In this review, we first focus on the regulation of miR-200c expression and its role in regulating EMT in a ZEB1/E-cadherin axis-dependent and ZEB1/E-cadherin axis-independent manner. We then describe the role of miR-200c in therapy resistance in terms of multidrug resistance, chemoresistance, targeted therapy resistance, and radiotherapy resistance in various cancer types. We highlight the importance of miR-200c at the intersection of EMT and chemoresistance. Furthermore, we show how miR-200c coordinates several important signaling cascades such as TGF-β signaling, PI3K/Akt signaling, Notch signaling, VEGF signaling, and NF-κB signaling. Finally, we discuss miR-200c as a potential prognostic/diagnostic biomarker in several diseases, but mainly focusing on cancer and its potential application in future therapeutics.
      Keywords
      Biomarker
      Cell signaling
      Drug resistance
      Epithelial-mesenchymal transition (EMT)
      miR-200c
      TGF-β
      ZEB1/2
      Immunoglobulin enhancer binding protein
      MicroRNA 200c
      Phosphatidylinositol 3 kinase
      Transcription factor ZEB1
      Transforming growth factor beta
      Uvomorulin
      Vasculotropin
      Antineoplastic agent
      Cadherin
      CDH1 protein, human
      MicroRNA
      MIRN200 microRNA, human
      Transcription factor ZEB1
      Transforming growth factor beta
      ZEB1 protein, human
      ZEB2 protein, human
      Zinc finger E box binding homeobox 2
      Cancer growth
      Cancer resistance
      Chemotherapy resistance
      Epithelial mesenchymal transition
      Gene expression
      Guard dog
      Multidrug resistance
      Nonhuman
      Radiotherapy resistance
      Review
      Therapy resistance
      Animal
      Cell transformation
      Disease exacerbation
      Drug resistance
      Epithelial mesenchymal transition
      Gene expression regulation
      Genetics
      Human
      Metabolism
      Neoplasm
      Pathology
      Signal transduction
      Animals
      Antineoplastic Agents
      Cadherins
      Cell Transformation, Neoplastic
      Disease Progression
      Drug Resistance, Neoplasm
      Epithelial-Mesenchymal Transition
      Gene Expression Regulation, Neoplastic
      Humans
      MicroRNAs
      Neoplasms
      Signal Transduction
      Transforming Growth Factor beta
      Zinc Finger E-box Binding Homeobox 2
      Zinc Finger E-box-Binding Homeobox 1
      Permalink
      http://hdl.handle.net/11693/38109
      Published Version (Please cite this version)
      https://doi.org/10.1007/s00109-016-1420-5
      Collections
      • Department of Molecular Biology and Genetics 512
      Show full item record

      Related items

      Showing items related by title, author, creator and subject.

      • Thumbnail

        TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT 

        Hill, R.; Madureira, P. A.; Ferreira, B.; Baptista, I.; Machado, S.; Colaço, L.; Dos Santos, M.; Liu, N.; Dopazo, A.; Ugurel, S.; Adrienn, A.; Kiss-Toth, E.; Isbilen, M.; Gure, A. O.; Link, W. (Nature Publishing Group, 2017)
        Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. ...
      • Thumbnail

        Enhancer cooperativity as a novel mechanism underlying the transcriptional regulation of E-cadherin during mesenchymal to epithelial transition 

        Alotaibi, H.; Basilicata, M. F.; Shehwana, H.; Kosowan, T.; Schreck, I.; Braeutigam, C.; Konu, O.; Brabletz, T.; Stemmler, M. P. (Elsevier, 2015)
        Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) highlight crucial steps during embryogenesis and tumorigenesis. Induction of dramatic changes in gene expression and cell features is ...
      • Thumbnail

        Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's disease 

        Gül, A.; Özbek, U.; Öztürk, C.; Inanç, M.; Koniçe, M.; Özçelik, T. (Oxford University Press, 1996)
        We investigated the prevalence of the coagulation factor V gene G1691A mutation in 64 patients with Behcet's disease (BD) and in 107 apparently healthy individuals. The mutation was present in the heterozygous state in ...

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy